Semaglutide and knee osteoarthritis: pain, function and what STEP 9 did not measure

In STEP 9, adults with obesity and symptomatic knee osteoarthritis assigned to injected semaglutide had larger average improvements in pain and body weight than those assigned to placebo. Both groups received lifestyle counseling. The trial measured symptoms and physical function, and did not establish cartilage repair. Knee osteoarthritis is not a labeled Wegovy indication.¹²

Read the pain outcome on its own scale

STEP 9 enrolled 407 people with obesity, clinical and radiographic knee osteoarthritis and at least moderate pain. At 68 weeks, the average WOMAC pain score had decreased 41.7 points in the semaglutide group and 27.5 points in the placebo group. The score runs from 0 to 100, with higher scores reflecting worse pain. A point change on that scale is not a percentage of cartilage restored or a promise that any person will experience the average.¹

Mean weight change was also greater in the semaglutide group. The trial reported better physical function as a separate outcome. It tested the overall difference between assigned groups. It does not establish how much of the pain effect came from weight change, activity, another mechanism or some combination of factors.¹

The population limits what you can take from it

The participants had both obesity and diagnosed knee osteoarthritis. The study cannot predict the same effect for knee pain from an unrelated injury, a different joint, or a person whose weight and diagnosis do not resemble the studied population. It also does not compare semaglutide with a knee procedure or establish where it belongs in an individual’s arthritis care.¹

A clinic might describe this as evidence relevant to a weight-care conversation for a person who also has knee osteoarthritis. Calling it an FDA-approved knee treatment goes beyond the current indication. Ask a practice making that claim which exact product and label section it means.²

Pay attention to what the placebo group received

Both trial groups received counseling, and the placebo group also showed a sizable average reduction in its pain score. The 41.7-point change is the change observed in the semaglutide group from its own baseline. It is not the difference between the groups. That distinction helps when a clinic quotes a before-and-after result without saying what happened in the comparison group. For an individual consultation, separate the goal of managing weight from the goal of improving a particular task. Either can be relevant without making pain improvement a guaranteed consequence of weight change.¹

Make room for both care goals

For a medical weight management consultation, identify the goal that matters to you: walking comfortably, a change in weight, less pain during a specific task, or something else. Bring the knee diagnosis if available and identify the clinician who manages the joint condition. Ask how the two clinicians will share observations, and which measures they will use to tell whether the plan is addressing each goal.